AD

TIER IV shares verification and validation toolkit for Level 4 autonomous driving functions

Retrieved on: 
Tuesday, November 7, 2023
TIER, Transport in Japan, Data, Safety, Government, AD, Certification, V&V, Level 4, Information, Medical device

TOKYO, Nov. 7, 2023 /PRNewswire/ -- TIER IV , a pioneer in open-source autonomous driving (AD) technology, announces the launch of L4 V&V , a comprehensive evaluation toolkit for verifying and validating Level 4 AD functions.

Key Points: 
  • TOKYO, Nov. 7, 2023 /PRNewswire/ -- TIER IV , a pioneer in open-source autonomous driving (AD) technology, announces the launch of L4 V&V , a comprehensive evaluation toolkit for verifying and validating Level 4 AD functions.
  • With this toolkit, TIER IV will contribute to accelerating the implementation of autonomous driving in society.
  • "By combining TIER IV's L4 V&V and our verification experience, as well as testing technologies utilizing our know-how, we believe we can support our customers with their autonomous driving vehicle development and evaluation for Level 4 autonomous driving approval."
  • Starting with TIER IV's L4 V&V, I look forward to the improvement and advancement of evaluation and verification of autonomous driving in the future."

JPAR® Celebrates the Success of JPAR Wellness and Embarks on a Transformative Journey Toward Comprehensive Agent Benefits

Retrieved on: 
Tuesday, November 7, 2023
WHO, Insurance, AD, Real estate, Accidental death, Health, Life, Family, Avibras, AD&D, Partnership, Retirement, Health insurance coverage in the United States, Wellness, Medicine, Property management, Health insurance, Video game

PLANO, Texas, Nov. 7, 2023 /PRNewswire/ -- JPAR®, a leading real estate brand, proudly announces the launch of JPAR Wellness, an integral part of the innovative Whole Health Organization (WHO) initiative, as a comprehensive three-part rollout of agent benefits. On the heels of a successful owners' event, this launch demonstrates JPAR is at the forefront of revolutionizing how real estate professionals are supported and reinforcing its commitment to the overall well-being of its network of over 4,000 agents nationwide.

Key Points: 
  • It brought valuable services, including 24/7 access to wellness advisors, discounts on essential services, insurance coverage, and customizable packages.
  • The core of JPAR Wellness is the profound belief in the importance of holistic health and well-being for every agent.
  • "No other brand is stepping up like JPAR to address the whole health of every agent," said Chris Sears, President, JPAR® - Real Estate.
  • Visit https://jparready.com/ to learn more about becoming a JPAR® - Real Estate agent and the benefits offered to its network of real estate professionals.

oToBrite Unveils Automotive-Grade 5MP/8MP Camera Modules to Meet Soaring Demand for High-Level ADAS/Autonomous Driving

Retrieved on: 
Tuesday, November 7, 2023
AD, SONY, Temperature, ADAS, Original equipment manufacturer, Sony, XPENG, CMOS, SKU, AI, Rhonda Software, Perception, Build automation, Advanced driver-assistance system, Satellite navigation device, Luxgen

With the need for enhanced perception technology, particularly for heavy commercial vehicles, as the heavier the vehicle is, the longer it will take to stop, oToBrite has successfully introduced automotive-grade 5MP/8MP camera modules.

Key Points: 
  • With the need for enhanced perception technology, particularly for heavy commercial vehicles, as the heavier the vehicle is, the longer it will take to stop, oToBrite has successfully introduced automotive-grade 5MP/8MP camera modules.
  • These cutting-edge modules can improve the visibility and perception capabilities of ADAS/AD systems, and have been adopted among clients in North America.
  • The newly launched 5MP/8MP camera modules from oToBrite feature high-sensitivity CMOS sensors.
  • Additionally, the in-house developed 5/6-axis active alignment machine for high-end camera modules exhibits the capability to manufacture over 60 SKU variants of camera modules.

Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published today

Retrieved on: 
Tuesday, November 7, 2023
AD, Alzheimer's disease, Neurology, Co-promotion, IDN, CET, Patient, EU, Arms industry, Pharmaceutical industry, Biogen, Eisai

BioArctic has the right to high single digit royalty on global sales of LEQEMBI.

Key Points: 
  • BioArctic has the right to high single digit royalty on global sales of LEQEMBI.
  • BioArctic's complete interim report for the third quarter 2023 will be published on November 8 at 08:00 CET.
  • This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 7, 2023, at 09:15 a.m. CET.

Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published today

Retrieved on: 
Tuesday, November 7, 2023
AD, Alzheimer's disease, Neurology, Co-promotion, IDN, CET, Patient, EU, Arms industry, Pharmaceutical industry, Biogen, Eisai

BioArctic has the right to high single digit royalty on global sales of LEQEMBI.

Key Points: 
  • BioArctic has the right to high single digit royalty on global sales of LEQEMBI.
  • BioArctic's complete interim report for the third quarter 2023 will be published on November 8 at 08:00 CET.
  • This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 7, 2023, at 09:15 a.m. CET.

Global Times: Preservation of Mogao Caves murals enthralls visiting Syrian delegation

Retrieved on: 
Tuesday, November 7, 2023
UNESCO, Painting, AD, Manuscript, Belt, Antiquities, Global Times, Central Academy, Dunhuang Research Academy, Silk, Face, Han dynasty, Silk Road, Learning, BRI, Tourism, Real-time, Culture, Yuan dynasty, Belt and Road Initiative, Cohesion (computer science), World Heritage Site, Psalms, Book, Museum, Party, Mogao Caves, Cave

Yousef, who works at the Directorate-General for Antiquities and Museums (DGAM), a Syrian government-owned agency responsible for protection and excavation activities in Syria's national heritage sites, is among a 24-person Syrian cultural delegation visiting China to explore cultural cooperation opportunities.

Key Points: 
  • Yousef, who works at the Directorate-General for Antiquities and Museums (DGAM), a Syrian government-owned agency responsible for protection and excavation activities in Syria's national heritage sites, is among a 24-person Syrian cultural delegation visiting China to explore cultural cooperation opportunities.
  • A biblical Psalms written in Syriac was discovered during an archeological excavation expedition at the Cave B53 of Mogao in 1986.
  • The digitalization of Mogao Caves has massively boosted the dissemination of information about the Mogao Caves worldwide, as the free-access portal "E-Dunhuang" was launched online in 2017, attracting over 20 million visitors worldwide.
  • "With the digitization of the resources, we can create high-resolution replicas of the caves and the murals to show them to audiences around the world."

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

Retrieved on: 
Monday, November 6, 2023
AD, Pharmacokinetics, ABOS, Patient, Pharmaceutical industry, Acumen, Halozyme

The collaboration will provide Acumen access to Halozyme's ENHANZE® drug delivery technology, based on a recombinant human hyaluronidase PH20 enzyme (rHuPH20), for the development of a subcutaneous formulation of ACU193, the first clinical-stage AβO-targeting antibody.

Key Points: 
  • The collaboration will provide Acumen access to Halozyme's ENHANZE® drug delivery technology, based on a recombinant human hyaluronidase PH20 enzyme (rHuPH20), for the development of a subcutaneous formulation of ACU193, the first clinical-stage AβO-targeting antibody.
  • ENHANZE® has been commercially validated in seven approved therapies, with global collaborations covering more than 60 therapeutic targets.
  • Under the terms of the agreement, in return for an upfront payment to Halozyme and other considerations, Acumen will receive non-exclusive rights to ENHANZE®.
  • Acumen is obligated to make future payments to Halozyme, subject to achievement of specified development, regulatory and sales-based milestones.

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 6, 2023
Shift, Research, AD, Food, Medicare, FOCUS, Narcolepsy, Doctor of Philosophy, Fibromyalgia, Prescription, New Drug Application, Agitation, Shift work, Shirin David, Physician, SG, Acquisition, Smoking, Amgen, Webcast, Somnolence, NDA, Safety, Therapy, Patient, Food and Drug Administration, Central nervous system, Eli Lilly and Company, Reboxetine, SWD, ES, MD, Migraine, Growth, Binge eating disorder, Breakthrough therapy, Total, FDA, Government, SYMPHONY, CMC, CNS, R, DSM-IV codes, Horizon Therapeutics, BED, Dextromethorphan/bupropion, NMDA, Eating disorder, Beauty salon, Video game, Pharmaceutical industry, Bank, Dietary supplement, Solriamfetol, ADHD, Medicaid

“Results for the third quarter evidenced significant revenue momentum for Axsome driven by solid performance from both Auvelity and Sunosi.

Key Points: 
  • “Results for the third quarter evidenced significant revenue momentum for Axsome driven by solid performance from both Auvelity and Sunosi.
  • Auvelity® net product sales were $37.7 million for the third quarter of 2023, representing a 36% sequential increase versus the second quarter of 2023.
  • Third quarter 2023 U.S. Sunosi total prescriptions increased by 16% versus the third quarter of 2022, and sequentially by 5% versus the second quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss third quarter 2023 financial results as well as to provide a corporate update.

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, November 6, 2023
Janus, Research, Lilly, Eli Lilly and Company, AD, Plasma, Half-life, PD, Psoriatic arthritis, Washington University in St. Louis, Biomarker, JAK3, EPI, G&A, Health, Rheumatoid arthritis, MAD, JAK, R, RA, ITK, ACRS, Ulcerative colitis, Osteoporosis, Pharmacokinetics, Hidradenitis suppurativa, PK, Methotrexate, Pancreatic cancer, Safety, Atopic dermatitis, Collection, Chapter 11, Title 11, United States Code, Therapy, Patient, MK2, Pharmaceutical industry, Vaccine, Palladium, Cryptocurrency, Rare-earth element, Tobacco, Hydraulic machinery

WAYNE, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2023 and provided a corporate update.

Key Points: 
  • Net loss was $29.3 million for the third quarter of 2023 compared to $20.0 million for the third quarter of 2022.
  • Total revenue was $9.3 million for the third quarter of 2023 compared to $19.0 million for the third quarter of 2022.
  • Research and development (R&D) expenses were $23.9 million for the quarter ended September 30, 2023 compared to $23.7 million for the prior year period.
  • General and administrative (G&A) expenses were $7.1 million for the quarter ended September 30, 2023 compared to $5.8 million for the corresponding prior year period.

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit

Retrieved on: 
Friday, November 3, 2023
Drug development, Type, AD, Dermatology, Eosinophilic bronchitis, Duke University, Johns Hopkins School of Medicine, Mortality, Cytokine, CCL3, Research, Inflammation, DDDS, Dupilumab, Research fellow, Biology, Constriction, ASLN, Chemokine, Head, AHR, Atopic dermatitis, International Society, Patient, Chronic obstructive pulmonary disease, CCL4, SAN, Pharmaceutical industry, COPD

ASLAN also presented new data investigating the role of eblasakimab in COPD using an established ex vivo model of precision cut lung slices from human donors2.

Key Points: 
  • ASLAN also presented new data investigating the role of eblasakimab in COPD using an established ex vivo model of precision cut lung slices from human donors2.
  • The model tested airway hyperresponsiveness (AHR) in the lung tissue using IL-4 and IL-13, the key Th2 cytokines involved in COPD disease pathology3.
  • Furthermore, IL-4 and IL-13 sensitized the airways to further constriction in response to methacholine, but this sensitization was blocked by eblasakimab treatment.
  • The presentation from Drug Development Summit can be accessed via the ASLAN website here .